Enveda Biosciences Advances ENV-294 to Phase 2 Trials After Promising Phase 1b Data Rivaling Dupixent in Atopic Dermatitis
Enveda initiated two parallel Phase 2a clinical trials for ENV-294, a first-in-class oral small molecule, in moderate-to-severe atopic dermatitis (AD) and asthma, following positive interim Phase 1b data in AD.3
Interim Phase 1b analysis showed ENV-294 with rapid onset, robust EASI improvements akin to JAK-inhibitors, and a biologic-like safety profile in moderate-to-severe AD patients.3
ENV-294 targets a novel non-kinase inflammatory pathway, offering an oral alternative to injectables like Dupixent (dupilumab).3
Enveda plans to start a Phase 2b dose-ranging study in AD in 2026, accelerating development as a 'pipeline-in-a-product' for inflammatory diseases.3
Earlier in May 2025, Enveda reported favorable Phase 1 safety for ENV-294 and launched Phase 1b in AD.6
Sources:
3. https://www.biospace.com/press-releases/enveda-initiates-phase-2-clinical-trials-of-env-294-a-first-in-class-oral-therapy-in-atopic-dermatitis-and-asthma